Construction of rBCG carrying the IL-2-BZLF1 fusion gene and its immunological function.
Appl Microbiol Biotechnol
; 108(1): 19, 2024 Dec.
Article
em En
| MEDLINE
| ID: mdl-38170315
ABSTRACT
In this research, a recombinant Bacillus Calmette Guerin (rBCG) vector vaccine carrying a human IL-2 and EBV BZLF1 fusion gene (IL-2-BZLF1-rBCG) was constructed. The IL-2-BZLF1-rBCG construct was successfully generated and stably expressed the IL-2 and BZLF1 proteins. IL-2-BZLF1-rBCG activated the immune system and promoted the secretion of IFN-γ and TNF-α by CD4+ and CD8+ T cells. IL-2-BZLF1-rBCG activated lymphocytes to effectively kill EBV-positive NPC cells in vitro. Additionally, IL-2-BZLF1-rBCG stimulated the proliferation of NK cells and lymphocytes in vivo, activated related immune responses, and effectively treated EBV-positive NPC. The immune response to and pharmacological effect of IL-2-BZLF1-rBCG were explored in vitro and in vivo to provide a theoretical and experimental basis for the prevention and treatment of EBV-positive tumors with an rBCG vector vaccine. KEY POINTS ⢠rBCG with human IL-2 and BZLF1 of EB virus was constructed ⢠The IL-2-BZLF1 fusion gene was stably expressed with rBCG ⢠rBCG with IL-2-BZLF1 has an obvious immune response in vitro and in vivo.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Mycobacterium bovis
/
Neoplasias
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article